公开(公告)号：WO2013156031A3

公开(公告)日：2013-12-12

申请号：PCT/DK2013050107

申请日：2013-04-17

Applicant: UNIV AARHUS

Inventor： PEDERSEN KAREN-MARIE ,  NYKJAER ANDERS ,  KJOELBY MADS FUGLSANG

IPC: A61K38/17 ,  A61P3/00

CPC classification number: C07K14/705 ,  A61K38/177 ,  A61K47/60 ,  A61K47/61

Abstract: The present invention relates to SorCS1-like agents, including SorCS1, nucleic acid molecule encoding expression of SorCS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing SorCS1 and said fragments, for use in a method of reducing appetite, and/or for promoting weight loss, and/or for treating obesity, and/or for increasing metabolism, and/or for increasing thermogenesis, and/or for converting white fat into brown fat

Abstract translation: 本发明涉及SorCS1样试剂，包括SorCS1，编码SorCS1表达的核酸分子及其片段，以及含有所述核酸的载体和表达SorCS1和所述片段的细胞，用于降低食欲的方法， 和/或用于促进体重减轻和/或治疗肥胖，和/或增加新陈代谢和/或增加产热，和/或将白脂肪转化为棕色脂肪

公开(公告)号：WO2013091661A3

公开(公告)日：2013-08-15

申请号：PCT/DK2012050505

申请日：2012-12-21

Applicant: UNIV AARHUS

Inventor： DIONISIO GIUSEPPE ,  BRINCH-PEDERSEN HENRIK ,  ROSENKILDE ANNE LIND

IPC: C12N15/62 ,  C07K7/06 ,  C07K7/08 ,  C12N9/02 ,  C12N15/81

CPC classification number: C12N9/0036 ,  C07K1/22 ,  C07K7/06 ,  C07K7/08 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/23 ,  C07K2319/24 ,  C07K2319/35 ,  C07K2319/50

Abstract: A protein tag is provided, which comprise a Proline-X-Proline (PXP) amino acid motif, wherein X is selected from any amino acid. Furthermore, fusion polypeptides and host cell comprising the proteintag is provided, as well as nucleic acids encoding these. Moreover, methods are provided of producing recombinant protein by culturing the host cell, expression a fusion polypeptide, and isolating the fusion polypeptide from the culture.

Abstract translation: 提供了蛋白质标签，其包含脯氨酸-X-脯氨酸（PXP）氨基酸基序，其中X选自任何氨基酸。 此外，提供了包含蛋白质标签的融合多肽和宿主细胞，以及编码它们的核酸。 此外，提供了通过培养宿主细胞，表达融合多肽并从培养物中分离融合多肽来产生重组蛋白的方法。

公开(公告)号：WO2010130990A8

公开(公告)日：2011-03-03

申请号：PCT/GB2010000941

申请日：2010-05-11

Applicant: ROTHAMSTED RES LTD ,  UNIV AARHUS ,  BIRKETT MIKE ,  PICKETT JOHN ,  DEWHIRST SARAH ,  JESPERSEN JOERGEN BROECHNER ,  STEENBERG TOVE ,  KILPINEN OLE OESTERLUND

Inventor： BIRKETT MIKE ,  PICKETT JOHN ,  DEWHIRST SARAH ,  JESPERSEN JOERGEN BROECHNER ,  STEENBERG TOVE ,  KILPINEN OLE OESTERLUND

IPC: A01N37/02 ,  A01M1/02 ,  A01N25/18 ,  A01N25/34 ,  A01N35/02 ,  A01P7/02 ,  A01P19/00

CPC classification number: A01N35/02 ,  A01N37/02

Abstract: The invention relates to the use of a volatile carboxylic acid or an aldehyde as an attractant for an avian mite and methods and systems thereof.

Abstract translation: 本发明涉及挥发性羧酸或醛作为禽螨的引诱剂的用途及其方法和系统。

公开(公告)号：WO2010097090A3

公开(公告)日：2010-11-25

申请号：PCT/DK2010050049

申请日：2010-02-25

Applicant: UNIV AARHUS ,  MJOELNER INFORMATICS AS ,  GAMMELGAARD CHRISTIAN HORSDAL ,  SKYUM SVEN ,  DALSGAARD SOEREN PINGEL ,  JOERGENSEN AKSEL BYSKOV

Inventor： GAMMELGAARD CHRISTIAN HORSDAL ,  SKYUM SVEN ,  DALSGAARD SOEREN PINGEL ,  JOERGENSEN AKSEL BYSKOV

IPC: G06F21/10 ,  G06F21/12 ,  G06F21/50

CPC classification number: G06F21/10 ,  G06F21/126 ,  G06F21/50 ,  G06F2221/2101 ,  G06F2221/2103 ,  G06F2221/2149

Abstract: The present invention relates to an authorized operating system environment and ensuring that a computer is running the authorized operating system environment. The invention provides a method that improves the security of virtual machines. A computer operating in the authorized operating system environment is adapted to send notification signals to a verification server. The signal comprises information identifying the computer. In case the verification server fails to receive a valid notification signal from the computer within a specified time, the verification server will provide a fault indication. The invention also provides an associated operating system environment and other aspects.

Abstract translation: 本发明涉及授权的操作系统环境，并确保计算机正在运行授权的操作系统环境。 本发明提供了一种提高虚拟机安全性的方法。 在授权的操作系统环境中操作的计算机适于向验证服务器发送通知信号。 信号包括识别计算机的信息。 如果验证服务器在指定时间内未能从计算机接收到有效的通知信号，则验证服务器将提供故障指示。 本发明还提供了相关的操作系统环境和其他方面。

公开(公告)号：WO2010112034A2

公开(公告)日：2010-10-07

申请号：PCT/DK2010050077

申请日：2010-04-06

Applicant: UNIV AARHUS ,  JENSEN POUL HENNING ,  LUND KRAGH CHRISTINE

Inventor： JENSEN POUL HENNING ,  LUND KRAGH CHRISTINE

IPC: C12N15/11

CPC classification number: C12N15/113 ,  C12N2310/14

Abstract: A method of treating a neurodegenerative disorder is provided, wherein compound, which inhibits or down-regulates the expression of a gene selected from the group consisting of Gadd45a, Gadd45b, Gadd45g, Nfkbia, Bbc3/PUMA, Ninji, Ccl2, Ccl7, Clcfl, Csfl, CxcH, Cxcl2, CxcH 0, IL6, Bhlhb2, Camkk2, Duspi, Lphn2, RiI, Hmoxi, Hspal a, Myd1 16, Srxni, Egr1, Fos, FosL, Hes1, KIfI O, Myc, Kpnai, SId 5a4, Slc35b2, Stx1 1, and Nudt18. Pharmaceutical compositions for use in such methods of treatment are also provided, as well as diagnostic kits comprising a detection member for detecting the expression of the genes involved in neurodegenerative disorders. Additionally, a method for identifying novel compounds for treatment of a neurodegenerative disorder is provided, which is based on detection of expression levels of the causative genes.

Abstract translation: 提供一种治疗神经变性疾病的方法，其中抑制或下调选自Gadd45a，Gadd45b，Gadd45g，Nfkbia，Bbc3 / PUMA，Ninji，Ccl2，Ccl7，Clcfl， Cs1c，CxcH，Cxcl2，CxcH0，IL6，Bhlhb2，Camkk2，Duspi，Lphn2，RiI，Hmoxi，Hspal a，Myd16，Srxni，Egr1，Fos，FosL，Hes1，KIfI O，Myc，Kpnai，SId 5a4，Slc35b2 ，Stx1 1和Nudt18。 还提供了用于这种治疗方法的药物组合物，以及包含用于检测涉及神经变性疾病的基因表达的检测成员的诊断试剂盒。 另外，提供了一种用于鉴定用于治疗神经变性疾病的新化合物的方法，其基于检测致病基因的表达水平。

公开(公告)号：WO2010022740A3

公开(公告)日：2010-05-14

申请号：PCT/DK2009050221

申请日：2009-08-28

Applicant: UNIV AARHUS ,  REGION MIDTJYLLAND ,  DUCH MOGENS RYTTERGAARD ,  PEDERSEN FINN SKOU ,  BAHRAMI SHERVIN ,  FREDSTED PALLE VILLESEN ,  WIUF CARSTEN ,  OESTERGAARD LARS JOERGEN ,  TOLSTRUP MARTIN

Inventor： DUCH MOGENS RYTTERGAARD ,  PEDERSEN FINN SKOU ,  BAHRAMI SHERVIN ,  FREDSTED PALLE VILLESEN ,  WIUF CARSTEN ,  OESTERGAARD LARS JOERGEN ,  TOLSTRUP MARTIN

IPC: C07K14/16 ,  A61K39/21 ,  C07K16/10 ,  C12N15/49

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  C12N2740/13034 ,  C12N2740/16122 ,  C12N2740/16134

Abstract: Immunogenic HIV-1 envelope polypeptides are provided, wherein specificamino acid residues are mutated to repress immunosuppression in GP41, thereby boosting the immune response against HIV-1. Specifically, mutation of those specific residues does not affect the fusogenic propertiesof the viral particleand/or the overall protein structure of the viral envelope protein.The invention further provides peptides and antigens based on the immunogenic HIV-1 envelopes as well as nucleic acid sequences and vectors encoding those. Moreover, biological entities such as viral particles are provided, as well as use of the provided components for preparation of a vaccine against HIV-1/AIDS.

Abstract translation: 提供免疫原性HIV-1包膜多肽，其中特异性氨基酸残基被突变以抑制GP41中的免疫抑制，从而增强针对HIV-1的免疫应答。 具体地说，这些特异性残基的突变不影响病毒颗粒的融合特性和/或病毒包膜蛋白的整体蛋白质结构。本发明还提供了基于免疫原性HIV-1包膜以及核酸序列的肽和抗原， 编码这些的向量。 此外，提供了诸如病毒颗粒的生物实体，以及使用所提供的组分来制备针对HIV-1 / AIDS的疫苗。

公开(公告)号：WO2009092806A2

公开(公告)日：2009-07-30

申请号：PCT/EP2009050796

申请日：2009-01-23

Applicant: UNIV AARHUS ,  OXVIG CLAUS ,  MIKKELSEN JAKOB HAUGE ,  NIELSEN CLAUS GYRUP

Inventor： OXVIG CLAUS ,  MIKKELSEN JAKOB HAUGE ,  NIELSEN CLAUS GYRUP

IPC: C07K14/435 ,  A61K38/17 ,  C07K14/47 ,  C07K16/18 ,  C07K16/40 ,  C12N9/64

CPC classification number: C07K14/4715 ,  A61K38/00 ,  C07K16/40 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/6489

Abstract: The present invention relates in one embodiment to PAPP-A exosite(s) interactors such as antibodies which bind to a region comprising LNR3 of PAPP-A and efficiently inhibit proteolysis of IGFBP-4, but not -5. The region comprising LNR3 represents a substrate binding exosite, which can be targeted for selective proteolytic inhibition. Accordingly, the present invention relates in one embodiment to differential inhibition of natural protease substrates by exosite targeting.

Abstract translation: 本发明在一个实施方案中涉及PAPP-A外部位点相互作用因子，例如结合到包含PAPP-A的LNR3的区域并有效抑制IGFBP-4的蛋白水解而不是-5的抗体。 包含LNR3的区域表示底物结合外部位点，其可以靶向用于选择性蛋白水解抑制。 因此，本发明在一个实施方案中涉及通过外部靶向靶向差异抑制天然蛋白酶底物。

公开(公告)号：WO2009012786A3

公开(公告)日：2009-06-18

申请号：PCT/DK2008050184

申请日：2008-07-23

Applicant: UNIV AARHUS ,  KJEMS JOERGEN ,  HOWARD KENNETH ALAN ,  BESENBACHER FLEMMING ,  DELEURAN BENT

Inventor： KJEMS JOERGEN ,  HOWARD KENNETH ALAN ,  BESENBACHER FLEMMING ,  DELEURAN BENT

IPC: A61K31/713 ,  C12N15/11 ,  C12N15/113

CPC classification number: A61K31/713 ,  A01K2217/058 ,  A01K2227/105 ,  A61K9/5161 ,  A61K47/61 ,  C07K14/525 ,  C12N15/111 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2320/32

Abstract: The present invention provides nanoparticles for treatment of inflammatory diseases. The nanoparticles preferably comprise chitosan and a siRNA targeting a mRNA encoding a pro-inflammatory cytokine, such as e.g. tnf-alfa. A preferred route of administration of the nanoparticles is by injection intraperitoneally.

Abstract translation: 本发明提供了用于治疗炎性疾病的纳米颗粒。 纳米颗粒优选包含壳聚糖和靶向编码促炎细胞因子的mRNA的siRNA，例如， TNF-α阿尔法。 纳米颗粒的优选施用途径是通过腹膜内注射。

公开(公告)号：WO2008106984A3

公开(公告)日：2008-12-31

申请号：PCT/DK2008050057

申请日：2008-03-06

Applicant: UNIV AARHUS ,  KRAGH PETER MICHAEL ,  BOLUND LARS AXEL ,  SOERENSEN CHARLOTTE BRANDT ,  CORYDON THOMAS JUHL ,  GREGERSEN NIELS ,  BROSS PETER

Inventor： KRAGH PETER MICHAEL ,  BOLUND LARS AXEL ,  SOERENSEN CHARLOTTE BRANDT ,  CORYDON THOMAS JUHL ,  GREGERSEN NIELS ,  BROSS PETER

IPC: C12N15/85

CPC classification number: A01K67/0275 ,  A01K67/0271 ,  A01K2217/052 ,  A01K2227/108 ,  A01K2267/0331 ,  C12N15/8509 ,  C12N15/8778 ,  C12N2800/30 ,  C12N2800/90

Abstract: The present invention relates to a genetically modified pig as a model for studying breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex. The modified pig model displays one or more phenotypes associated with any of said disorders. Disclosed is also a modified pig comprising a modified endogeneous BRCA1 and/or BRCA 2 gene, and/or a modified ornithine transcarbamylase gene, and/or a modified Keratin 14 gene and/or a transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex are disclosed.

Abstract translation: 本发明涉及作为研究乳腺癌，线粒体相关蛋白折叠病症和/或大疱性表皮松解症的模型的基因修饰猪。 修饰的猪模型显示与任何所述病症相关的一种或多种表型。 还公开了包含修饰的内源性BRCA1和/或BRCA2基因和/或修饰的鸟氨酸转氨甲酰酶基因和/或修饰的角蛋白14基因和/或转录或翻译产物或其部分的修饰的猪。 本发明还涉及生产改良猪的方法; 以及用于评估乳腺癌，线粒体相关蛋白折叠障碍和/或大疱性表皮松解症的治疗性治疗效果的方法; 筛选药物组合物功效的方法; 以及用于治疗患有乳腺癌，线粒体相关蛋白折叠病症和/或大疱性表皮松解症的人的方法。

公开(公告)号：WO2008067815A8

公开(公告)日：2008-08-21

申请号：PCT/DK2007000530

申请日：2007-12-04

Applicant: UNIV AARHUS ,  MAX PLANCK GESELLSCHAFT ,  BENTIEN ANDERS ,  JOHNSEN SIMON ,  MADSEN GEORG KENT HELLERUP ,  IVERSEN BO BRUMMERSTEDT ,  STEGLICH FRANK

Inventor： BENTIEN ANDERS ,  JOHNSEN SIMON ,  MADSEN GEORG KENT HELLERUP ,  IVERSEN BO BRUMMERSTEDT ,  STEGLICH FRANK

IPC: H01L35/18

CPC classification number: H01L35/34 ,  C22C12/00 ,  C30B15/00 ,  C30B29/52 ,  H01L35/18

Abstract: The invention relates to the use of a thermoelectric material for thermoelectric purposes at a temperature of 150 K or less, said thermoelectric material is a material corresponding to the stoichiometric formula FeSb2, wherein all or part of the Fe atoms optionally being substituted by one or more elements selected from the group comprising: Sc, Ti, V, Cr, Mn, Co, Ni, Cu, Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, La, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu and a vacancy; and wherein all or part of the Sb atoms optionally being substituted by one or more elements selected from the group comprising: P, As, Bi, S, Se, Te, B, Al, Ga, In, Tl, C, Si, Ge, Sn, Pb and a vacancy; with the proviso that neither one of the elements Fe and Sb in the formula FeSb2 is fully substituted with a vacancy, characterised in that said thermoelectric material exhibits a power factor (S2s) of 25 µW/cmK2 or more at a temperature of 150 K or less. The invention also relates to thermoelectric materials per se falling within the above definition.

Abstract translation: 本发明涉及用于热电目的的热电材料在150K或更低的温度下的用途，所述热电材料是对应于化学计量分子式FeSb 2的材料，其中全部或部分Fe原子任选地被一个或多个 选自Sc，Ti，V，Cr，Mn，Co，Ni，Cu，Zn，Y，Zr，Nb，Mo，Tc，Ru，Rh，Pd，Ag，Cd，La，Hf，Ta ，W，Re，Os，Ir，Pt，Au，Hg，Ce，Pr，Nd，Pm，Sm，Eu，Gd，Tb，Dy，Ho，Er，Tm，Yb，Lu和空位; 并且其中全部或部分Sb原子任选地被一种或多种选自P，As，Bi，S，Se，Te，B，Al，Ga，In，Tl，C，Si，Ge ，锡，铅和空位; 条件是式FeSb2中的元素Fe和Sb中的任何一个完全被空位取代，其特征在于所述热电材料在150K的温度下表现出25μW/ cmK2或更高的功率因数（S2s）或者 减。 本发明还涉及属于上述定义的热电材料本身。